178 related articles for article (PubMed ID: 29511574)
1. Comparison of Glycomacropeptide with Phenylalanine Free-Synthetic Amino Acids in Test Meals to PKU Patients: No Significant Differences in Biomarkers, Including Plasma Phe Levels.
Ahring KK; Lund AM; Jensen E; Jensen TG; Brøndum-Nielsen K; Pedersen M; Bardow A; Holst JJ; Rehfeld JF; Møller LB
J Nutr Metab; 2018; 2018():6352919. PubMed ID: 29511574
[TBL] [Abstract][Full Text] [Related]
2. The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model.
Ahring KK; Dagnæs-Hansen F; Brüel A; Christensen M; Jensen E; Jensen TG; Johannsen M; Johansen KS; Lund AM; Madsen JG; Brøndum-Nielsen K; Pedersen M; Sørensen LK; Kjolby M; Møller LB
PLoS One; 2022; 17(1):e0261150. PubMed ID: 35015767
[TBL] [Abstract][Full Text] [Related]
3. Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU.
Daly A; Evans S; Chahal S; Santra S; Pinto A; Jackson R; Gingell C; Rocha J; Van Spronsen FJ; MacDonald A
Orphanet J Rare Dis; 2019 Feb; 14(1):44. PubMed ID: 30770754
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Glycomacropeptide versus Amino Acids on Phenylalanine and Tyrosine Variability over 24 Hours in Children with PKU: A Randomized Controlled Trial.
Daly A; Evans S; Chahal S; Santra S; Pinto A; Gingell C; Rocha JC; van Spronsen F; Jackson R; MacDonald A
Nutrients; 2019 Feb; 11(3):. PubMed ID: 30823411
[No Abstract] [Full Text] [Related]
5. Glycomacropeptide in children with phenylketonuria: does its phenylalanine content affect blood phenylalanine control?
Daly A; Evans S; Chahal S; Santra S; MacDonald A
J Hum Nutr Diet; 2017 Aug; 30(4):515-523. PubMed ID: 28111827
[TBL] [Abstract][Full Text] [Related]
6. Preliminary Investigation to Review If a Glycomacropeptide Compared to L-Amino Acid Protein Substitute Alters the Pre- and Postprandial Amino Acid Profile in Children with Phenylketonuria.
Daly A; Evans S; Pinto A; Jackson R; Ashmore C; Rocha JC; MacDonald A
Nutrients; 2020 Aug; 12(8):. PubMed ID: 32823853
[TBL] [Abstract][Full Text] [Related]
7. Casein glycomacropeptide in phenylketonuria: does it bring clinical benefit?
Daly A; Ilgaz F; Pinto A; MacDonald A
Curr Opin Clin Nutr Metab Care; 2024 Jan; 27(1):31-39. PubMed ID: 38085662
[TBL] [Abstract][Full Text] [Related]
8. Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria.
MacLeod EL; Clayton MK; van Calcar SC; Ney DM
Mol Genet Metab; 2010 Aug; 100(4):303-8. PubMed ID: 20466571
[TBL] [Abstract][Full Text] [Related]
9. Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria.
Solverson P; Murali SG; Brinkman AS; Nelson DW; Clayton MK; Yen CL; Ney DM
Am J Physiol Endocrinol Metab; 2012 Apr; 302(7):E885-95. PubMed ID: 22297302
[TBL] [Abstract][Full Text] [Related]
10. Nutritional management of PKU with glycomacropeptide from cheese whey.
Ney DM; Gleason ST; van Calcar SC; MacLeod EL; Nelson KL; Etzel MR; Rice GM; Wolff JA
J Inherit Metab Dis; 2009 Feb; 32(1):32-9. PubMed ID: 18956251
[TBL] [Abstract][Full Text] [Related]
11. Investigation of paediatric PKU breath malodour, comparing glycomacropeptide with phenylalanine free L-amino acid supplements.
Tiele A; Daly A; Hattersley J; Pinto A; Evans S; Ashmore C; MacDonald A; Covington JA
J Breath Res; 2019 Oct; 14(1):016001. PubMed ID: 31476741
[TBL] [Abstract][Full Text] [Related]
12. Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective.
Pena MJ; Pinto A; de Almeida MF; de Sousa Barbosa C; Ramos PC; Rocha S; Guimas A; Ribeiro R; Martins E; Bandeira A; Dias CC; MacDonald A; Borges N; Rocha JC
Orphanet J Rare Dis; 2021 Feb; 16(1):84. PubMed ID: 33581730
[TBL] [Abstract][Full Text] [Related]
13. The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria.
Daly A; Evans S; Pinto A; Jackson R; Ashmore C; Rocha JC; MacDonald A
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32899700
[TBL] [Abstract][Full Text] [Related]
14. Glycomacropeptide in PKU-Does It Live Up to Its Potential?
Daly A; Pinto A; Evans S; MacDonald A
Nutrients; 2022 Feb; 14(4):. PubMed ID: 35215457
[TBL] [Abstract][Full Text] [Related]
15. Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria.
Ney DM; Hull AK; van Calcar SC; Liu X; Etzel MR
J Nutr; 2008 Feb; 138(2):316-22. PubMed ID: 18203898
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.
Sawin EA; Murali SG; Ney DM
Mol Genet Metab; 2014 Apr; 111(4):452-61. PubMed ID: 24560888
[TBL] [Abstract][Full Text] [Related]
17. Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial.
Ney DM; Stroup BM; Clayton MK; Murali SG; Rice GM; Rohr F; Levy HL
Am J Clin Nutr; 2016 Aug; 104(2):334-45. PubMed ID: 27413125
[TBL] [Abstract][Full Text] [Related]
18. Casein Glycomacropeptide: An Alternative Protein Substitute in Tyrosinemia Type I.
Daly A; Evans S; Pinto A; Ashmore C; MacDonald A
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579102
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic Markers of Essential Fatty Acids, Carnitine, and Cholesterol Metabolism in Adults and Adolescents with Phenylketonuria.
Stroup BM; Nair N; Murali SG; Broniowska K; Rohr F; Levy HL; Ney DM
J Nutr; 2018 Feb; 148(2):194-201. PubMed ID: 29490096
[TBL] [Abstract][Full Text] [Related]
20. Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.
Solverson P; Murali SG; Litscher SJ; Blank RD; Ney DM
PLoS One; 2012; 7(9):e45165. PubMed ID: 23028819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
